Filing Details

Accession Number:
0000950170-24-138629
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-19 18:57:42
Reporting Period:
2024-12-18
Accepted Time:
2024-12-19 18:57:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582313 Xenon Pharmaceuticals Inc. XENE Pharmaceutical Preparations (2834) 980661854
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1862144 Sherry Aulin 200 - 3650 Gilmore Way
Burnaby A1 V5G 4W8
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2024-12-18 9,334 $9.44 9,334 No 4 M Direct
Common Shares Disposition 2024-12-18 2,135 $41.28 7,199 No 4 F Direct
Common Shares Disposition 2024-12-18 7,199 $41.23 0 No 4 S Direct
Common Shares Acquisiton 2024-12-18 16,000 $11.58 16,000 No 4 M Direct
Common Shares Disposition 2024-12-18 4,490 $41.28 11,510 No 4 F Direct
Common Shares Disposition 2024-12-18 11,510 $41.19 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2024-12-18 9,334 $0.00 9,334 $9.44
Common Shares Stock Option (Right to Buy) Disposition 2024-12-18 16,000 $0.00 16,000 $11.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2029-09-15 No 4 M Direct
6,000 2030-03-11 No 4 M Direct
Footnotes
  1. Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
  2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. The shares subject to the option are fully vested and exercisable.